Similar articles

• Immunohistology of liver allografts in recipients managed with prophylactic OKT3.

  Rohrer RJ, Jenkins RL, Khettry U, Pinson CW, Gallik-Karlson C, Monaco AP. Rohrer RJ, et al. Transplant Proc. 1989 Feb;21(1 Pt 2):2249-50. Transplant Proc. 1989. PMID: 2652729 Clinical Trial. No abstract available.
• Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients.

  McDiarmid SV, Millis M, Terashita G, Ament ME, Busuttil R, Terasaki P. McDiarmid SV, et al. Transplant Proc. 1990 Aug;22(4):1774-6. Transplant Proc. 1990. PMID: 2117806 Clinical Trial. No abstract available.
• A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.

  Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL. Cosimi AB, et al. Transplant Proc. 1987 Feb;19(1 Pt 3):2431-3. Transplant Proc. 1987. PMID: 3079083 Clinical Trial. No abstract available.
• Concomitant low-dose cyclosporine and OKT3 therapy for renal transplant rejection.

  Hricik DE, Zarconi J, Schulak JA. Hricik DE, et al. Transplant Proc. 1989 Feb;21(1 Pt 2):1755-7. Transplant Proc. 1989. PMID: 2652574 Clinical Trial. No abstract available.
• Clinical development of Orthoclone OKT3.

  Cosimi AB. Cosimi AB. Transplant Proc. 1987 Apr;19(2 Suppl 1):7-16. Transplant Proc. 1987. PMID: 3105142 Review. No abstract available.